# Phase 2 adenocarcinoma trials recruiting: 48 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 48 trials in phase 2 for adenocarcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 adenocarcinoma trials: 48 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/adenocarcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 48
- Recruiting or not yet: 48
- Read on: November 19, 2026

## Trials

The 25 newest of 48, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07912957 | Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ | Fudan University | Phase 2 | Not yet recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912957) |
| October 30, 2026 | NCT07907653 | Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced... | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Prostate Cancer (Adenocarcinoma) | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907653) |
| October 6, 2026 | NCT07859592 | Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma | VA Office of Research and Development | Phase 2 | Not yet recruiting | Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859592) |
| August 31, 2026 | NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | University of California, Irvine | Phase 2 | Recruiting | Esophageal Carcinoma, Gastric Cancer (Diagnosis), Colorectal Adenocarcinoma, Appendiceal Adenocarcinoma, Small Bowel... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795749) |
| August 10, 2026 | NCT07753824 | A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma... | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Phase II, Ivonescimab, Intraperitoneal, Paclitaxel, High Grade Metastatic, Appendiceal Adenocarcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753824) |
| August 4, 2026 | NCT07745361 | Study of Oral MRT-2359 With Apalutamide in Prostate Cancer | Monte Rosa Therapeutics, Inc | Phase 2 | Recruiting | Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745361) |
| August 3, 2026 | NCT07740993 | A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma | West China Hospital | Phase 2 | Not yet recruiting | Sebaceous Gland Carcinoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07740993) |
| July 22, 2026 | NCT07718854 | Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer | Tufts Medical Center | Phase 2 | Recruiting | Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer, Recurrent Ovarian Clear Cell Adenocarcinoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718854) |
| July 13, 2026 | NCT07699939 | Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction... | National Cancer Center, Japan | Phase 2 | Recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07699939) |
| July 9, 2026 | NCT07692334 | Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma | West China Second University Hospital | Phase 2 | Not yet recruiting | Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Becotatug Vedotin, Pucotenlimab | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07692334) |
| July 8, 2026 | NCT07689292 | Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689292) |
| June 1, 2026 | NCT07617272 | Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant... | Region Stockholm | Phase 2 | Recruiting | Prostate Cancer (Adenocarcinoma) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617272) |
| May 18, 2026 | NCT07592910 | A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor... | Prostate Cancer Clinical Trials Consortium | Phase 2 | Not yet recruiting | Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (Adenocarcinoma) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07592910) |
| May 8, 2026 | NCT07574541 | Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07574541) |
| April 7, 2026 | NCT07515651 | Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage... | University Health Network, Toronto | Phase 2 | Recruiting | Prostate Cancer (Adenocarcinoma) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515651) |
| April 2, 2026 | NCT07507916 | Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma | Fudan University | Phase 2 | Not yet recruiting | ctDNA, Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Adjuvant Treatment | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07507916) |
| January 27, 2026 | NCT07368985 | Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2, Adenocarcinoma or... | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07368985) |
| January 12, 2026 | NCT07332000 | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | Candel Therapeutics, Inc. | Phase 2 | Recruiting | Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07332000) |
| December 24, 2025 | NCT07302451 | REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients) | National Cancer Institute, Naples | Phase 2 | Recruiting | Prostate Cancer (Adenocarcinoma) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07302451) |
| December 15, 2025 | NCT07281768 | Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Recruiting | Colorectal Cancer | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07281768) |
| December 8, 2025 | NCT07268794 | CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer | Fudan University | Phase 2 | Not yet recruiting | Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268794) |
| December 2, 2025 | NCT07259317 | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Corcept Therapeutics | Phase 2 | Recruiting | Adenocarcinoma, Carcinoma, Pancreatic Ductal | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07259317) |
| September 18, 2025 | NCT07179783 | Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine... | Tianjin Medical University Second Hospital | Phase 2 | Recruiting | Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With... | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07179783) |
| June 26, 2025 | NCT07038304 | The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC) | University Medical Center Groningen | Phase 2 | Recruiting | Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease, Castration Resistant Metastatic Prostate Cancer... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07038304) |
| June 18, 2025 | NCT07026149 | Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer | Ruijin Hospital | Phase 2 | Recruiting | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07026149) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 4 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 3 |
| Prostate Cancer Clinical Trials Consortium | 2 |
| National Cancer Institute (NCI) | 2 |
| University of California, Irvine | 1 |
| National Cancer Center Hospital East | 1 |
| [Corcept Therapeutics](https://specstream.ai/data/clinical-trials/company/corcept-therapeutics) | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Toray Industries, Inc | 1 |
| City of Hope Medical Center | 1 |
| Cellvax Therapeutics Inc | 1 |
| Ruijin Hospital | 1 |
| Candel Therapeutics, Inc. | 1 |
| Centre Oscar Lambret | 1 |
| University Medical Center Groningen | 1 |
| National Cancer Center, Japan | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| West China Second University Hospital | 1 |
| Tufts Medical Center | 1 |
| Amsterdam UMC, location VUmc | 1 |
| THERABIONIC INC. | 1 |
| Region Stockholm | 1 |
| UNICANCER | 1 |
| West China Hospital | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 22 |
| China | 9 |
| Japan | 3 |
| Netherlands | 3 |
| South Korea | 3 |
| France | 2 |
| Italy | 2 |
| Sweden | 1 |
| Austria | 1 |
| Belgium | 1 |
| Czechia | 1 |
| Germany | 1 |
| Spain | 1 |
| Canada | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Bathtub and sink repair companies in the United States](https://specstream.ai/data/businesses/bathtub-and-sink-repair-companies/united-states)
- [Locksmiths in the United States](https://specstream.ai/data/businesses/locksmiths/united-states)
- [Air duct cleaning companies in the United States](https://specstream.ai/data/businesses/air-duct-cleaning-companies/united-states)
- [Home security companies in the United States](https://specstream.ai/data/businesses/home-security-companies/united-states)
- [Tobacco companies in the United States](https://specstream.ai/data/businesses/tobacco-companies/united-states)
- [Exporters in the United States](https://specstream.ai/data/businesses/exporters/united-states)
